PURPOSE: To study, using serial neuropsychological assessment and evaluation of school achievement, persistent neuropsychological late effects in children treated for acute lymphoblastic leukemia (ALL) at a young age with chemotherapy only. PATIENTS AND METHODS: Twenty consecutive patients underwent three evaluations, including 12 psychometric measures beside IQ. The authors applied strict methodology and a prospective-longitudinal design that started at diagnosis and extended to a median follow-up of 7 years. This report focuses on the outcome of the last evaluation. Test results were compared with healthy controls and to patients with ALL treated on a previous chemotherapy-only protocol. School achievement was evaluated in patients and their siblings. RESULTS: At the last evaluation, significantly lower test scores in patients compared with controls were found for only 2 of 14 cognitive measures (1 intelligence and 1 attention measure). No great differences were seen between school achievement of patients and siblings. Compared with the previous chemotherapy protocol, a better outcome was seen in the current study group on two measures (one memory and one attention measure). CONCLUSIONS: Children surviving ALL have no major cognitive impairment after chemotherapy, including intrathecal and high-dose intravenous methotrexate. The slightly better outcome in the current group may indicate possible adverse effects of more dexamethasone treatment in the previous group.
PURPOSE: To study, using serial neuropsychological assessment and evaluation of school achievement, persistent neuropsychological late effects in children treated for acute lymphoblastic leukemia (ALL) at a young age with chemotherapy only. PATIENTS AND METHODS: Twenty consecutive patients underwent three evaluations, including 12 psychometric measures beside IQ. The authors applied strict methodology and a prospective-longitudinal design that started at diagnosis and extended to a median follow-up of 7 years. This report focuses on the outcome of the last evaluation. Test results were compared with healthy controls and to patients with ALL treated on a previous chemotherapy-only protocol. School achievement was evaluated in patients and their siblings. RESULTS: At the last evaluation, significantly lower test scores in patients compared with controls were found for only 2 of 14 cognitive measures (1 intelligence and 1 attention measure). No great differences were seen between school achievement of patients and siblings. Compared with the previous chemotherapy protocol, a better outcome was seen in the current study group on two measures (one memory and one attention measure). CONCLUSIONS:Children surviving ALL have no major cognitive impairment after chemotherapy, including intrathecal and high-dose intravenous methotrexate. The slightly better outcome in the current group may indicate possible adverse effects of more dexamethasone treatment in the previous group.
Authors: Kathleen C Insel; Marilyn J Hockenberry; Lynette L Harris; Kari M Koerner; Zhenqiang Lu; Kristin B Adkins; Olga A Taylor; Patricia M Gundy; Ida M Moore Journal: Oncol Nurs Forum Date: 2017-07-01 Impact factor: 2.172
Authors: Wilburn E Reddick; Zuyao Y Shan; John O Glass; Susan Helton; Xiaoping Xiong; Shengjie Wu; Melanie J Bonner; Scott C Howard; Robbin Christensen; Raja B Khan; Ching-Hon Pui; Raymond K Mulhern Journal: Cancer Date: 2006-02-15 Impact factor: 6.860
Authors: Nina S Kadan-Lottick; Pim Brouwers; David Breiger; Thomas Kaleita; James Dziura; Haibei Liu; Lu Chen; Megan Nicoletti; Linda Stork; Bruce Bostrom; Joseph P Neglia Journal: Blood Date: 2009-06-22 Impact factor: 22.113
Authors: Marita Daams; Ilse Schuitema; Bob W van Dijk; Eline van Dulmen-den Broeder; Anjo Jp Veerman; Cor van den Bos; Leo Mj de Sonneville Journal: BMC Neurol Date: 2012-08-28 Impact factor: 2.474